title: Attenuation of muscle atrophy by an N-terminal peptide of the receptor for proteolysis-inducing factor (PIF).
abstract: BACKGROUND
  Atrophy of skeletal muscle in cancer cachexia has been attributed to a tumour-produced highly glycosylated peptide called proteolysis-inducing factor (PIF). The action of PIF is mediated through a high-affinity membrane receptor in muscle. This study investigates the ability of peptides derived from the 20 N-terminal amino acids of the receptor to neutralise PIF action both in vitro and in vivo.
  
  
  METHODS
  Proteolysis-inducing factor was purified from the MAC16 tumour using an initial pronase digestion, followed by binding on DEAE cellulose, and the pronase was inactivated by heating to 80°C, before purification of the PIF using affinity chromatography. In vitro studies were carried out using C(2)C(12) murine myotubes, while in vivo studies employed mice bearing the cachexia-inducing MAC16 tumour.
  
  
  RESULTS
  The process resulted in almost a 23,000-fold purification of PIF, but with a recovery of only 0.004%. Both the D- and L-forms of the 20mer peptide attenuated PIF-induced protein degradation in vitro through the ubiquitin-proteosome proteolytic pathway and increased expression of myosin. In vivo studies showed that neither the D- nor the L-peptides significantly attenuated weight loss, although the D-peptide did show a tendency to increase lean body mass.
  
  
  CONCLUSIONS
  These results suggest that the peptides may be too hydrophilic to be used as therapeutic agents, but confirm the importance of the receptor in the action of the PIF on muscle protein degradation.
authors.affiliation: Nutritional Biomedicine, School of Life and Health Sciences, Aston University, Birmingham B4 7ET, UK.
authors.forename: K A
authors.initials: KA
authors.lastname: Mirza
authors.forename: S M
authors.initials: SM
authors.lastname: Wyke
authors.forename: M J
authors.initials: MJ
authors.lastname: Tisdale
mesh_terms: D000818:Animals; D015153:Blotting, Western; D002100:Cachexia / Q000209:etiology* / Q000378:metabolism / Q000473:pathology; D002478:Cells, Cultured; D003110:Colonic Neoplasms / Q000378:metabolism / Q000473:pathology*; D008297:Male; D051379:Mice; D009124:Muscle Proteins / Q000378:metabolism*; D009133:Muscular Atrophy / Q000209:etiology* / Q000378:metabolism / Q000473:pathology; D032448:Myoblasts, Skeletal / Q000166:cytology / Q000378:metabolism; D010446:Peptide Fragments / Q000378:metabolism*; D011509:Proteoglycans / Q000037:antagonists & inhibitors / Q000302:isolation & purification / Q000378:metabolism*
chemical_list: D009124:Muscle Proteins; D010446:Peptide Fragments; D011509:Proteoglycans; C042057:proteolysis-inducing peptide